Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford

This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford.

Inclusion Criteria: * \>/= 18 years-old * Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or * Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and followed primarily by SHC Blood and Bone Marrow transplant providers * \>/= 6 months from the date of CAR-T infusion * Fluent in English * Able to attend and participate in in-person testing (Arm I) * Able to participate in remote video testing with adequate workspace, computer and internet capabilities for a reliable telehealth video connection (Arm II) Exclusion Criteria: * Concurrent enrollment in a CAR-T therapeutics research study * Unable to be present for the scheduled testing * Unable to participate in testing due to severe cognitive or physical limitation * Actively receiving chemotherapy * Progressive cancer